
Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Latest episodes

May 18, 2022 • 7min
Trending With Impact: Dual Requirement in Stem Cell Leukemia/Lymphoma
The podcast discusses the impact of chromosomal translocations in cancer, focusing on the BCR-FGFR1 fusion protein in SCLL. They explore the necessary interactions of GRB2 and PLC Gamma-1 for cell proliferation and potential therapeutic interventions in BCR-FGFR1-driven hematologic malignancies.

May 18, 2022 • 2min
Press Release: Impact Journals at SSP Annual Meeting
A discussion on Impact Journals' commitment to scientific integrity in biomedical sciences, focusing on ethics, peer review, plagiarism prevention, and image forensics. They will present these processes at the SSP Annual Meeting, covering cancer research, aging, and COVID-19 vulnerability.

Apr 28, 2022 • 7min
Paper Spotlight: Gene Variants Investigated in Polish Bladder and Kidney Cancer
Explore disparities in cancer rates between genders and the search for better biomarkers and treatments in bladder cancer. Analysis of genetic variants in Polish patients with bladder and kidney cancer, revealing insights on specific variants and their impact on patient survival.

Apr 26, 2022 • 8min
Trending With Impact: Analysis of Mutational Burden in NSCLC
Discover the significance of tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC) and its association with neoantigens and immune response. Learn about the shift to measuring TMB in mutations per megabase (>10 mut/Mb) and how high TMB levels can predict a positive response to immunotherapy in NSCLC patients. Explore the results of a cohort study on Stage 4 NSCLC patients, highlighting the impact of TMB on survival benefits and its correlation with smoking history and genetic alterations.

Apr 26, 2022 • 4min
Press Release: Mutational Burden in Lung Cancer Studied in Multisite Cohort
Researchers conducted a study on tumor mutational burden in non-small cell lung cancer, specifically looking at how TMB affects clinical outcomes in patients receiving immunotherapy. A high TMB may lead to a stronger immune response, making it a potential predictive biomarker for immuno-oncology treatment.

Apr 22, 2022 • 13min
Author Insight: How ONC201 Kills Breast Cancer Cells
Dr. Lipkowitz and Dr. Endo Greer from NCI discuss how ONC201 kills breast cancer cells by targeting mitochondria, not dependent on TRAIL receptors or caspases. ONC201 induces cell membrane ballooning and rupture, AMP-dependent kinase phosphorylation, and ATP loss, enhancing cytotoxicity in the absence of glucose. The drug indirectly inhibits mitochondrial respiration, showing potential in cancer therapy.

Apr 15, 2022 • 8min
Trending With Impact: Genes Identified in Endocrine Therapy Resistance
Researchers explore genes responsible for endocrine therapy resistance in breast cancer, utilizing advanced statistical and computational methods. They identify 34 crucial genes related to resistance and triple negative breast cancer, highlighting the need for better understanding to improve treatments.

Apr 14, 2022 • 9min
Author Insight: Secretomes from Metastatic Breast Cancer Cells and MSC Actions
Guests from California State University discuss a research paper on secretomes from metastatic breast cancer cells. They delve into the effects on premetastatic tissues, the role of CD73-positive mesenchymal stem cells, and the impact of lipocalin II in creating a tumor-supportive environment in the lung.

Apr 7, 2022 • 7min
Paper Spotlight: Novel Therapeutic Strategies Against Endometrial Cancer
The podcast explores the rise of endometrial cancer, the potential side effects of hysterectomies, and the research on the (pro)renin receptor in endometrial cancer biology. They discuss innovative therapeutic approaches, the role of PRR in cancer cell growth, viability, and its implications for diagnosis and treatment.

Mar 31, 2022 • 6min
Author Insight: Down Syndrome iPSC Model: Endothelial Perspective on Tumor Development
Researchers Mariana Perepitchka, Yekaterina Galat, and Dr. Vasiliy Galat discuss their 2020 research on Down syndrome iPSC model and tumor development. They explore the unique cancer profile of DS individuals, focusing on endothelial cells' role in preventing solid tumor growth. The podcast discusses molecular and phenotypic differences in DS endothelial cells, highlighting genes related to angiogenic pathways and potential new leukemia treatment targets.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.